Adults with type 2 diabetes may have a higher risk for developing nonarteritic anterior ischemic optic neuropathy while using ...

Eli Lilly and Boehringer Ingelheim’s Jardiance was the first diabetes drug to lower the risk of cardiovascular disease in a clinical trial, and is now on course to be the first to have a chronic ...

The FDA has granted a speedy review of Eli Lilly and Boehringer Ingelheim’s Jardiance for a potential new use, to reduce the risk of renal failure and cardiovascular death in people with chronic ...

Merck), empagliflozin (Jardiance; Boehringer Ingelheim/Eli Lilly), and insulin aspart (Fiasp and NovoLog; Novo Nordisk). Similarly, total spending for all 10 drugs increased from $3.5 to $27.5 billion ...

In pigs receiving anthracyclines, the researchers administered a 20 mg daily dose of the SGLT2 inhibitor empagliflozin, sold ...

Please provide your email address to receive an email when new articles are posted on . Seven cardiometabolic medications incur the most Medicare Part D spending among drugs up for price negotiation.

Rounding out the month’s top 10 was Jardiance, Eli Lilly and Boehringer Ingelheim’s treatment for Type 2 diabetes and chronic kidney disease. With $20.8 million, it rose two spots month over ...

In pigs receiving anthracyclines, the researchers administered a 20 mg daily dose of the SGLT2 inhibitor empagliflozin, sold as Jardiance by Boehringer Ingelheim. Empagliflozin increases the heart ...